Mohammad Javad Zahedi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohammad Javad Zahedi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Naghibzadeh-Tahami
Health Services Management Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran
6 shared publications - Ali Akbar Haghdoost
Kerman University of Medical Sciences
6 shared publications - Elham Mohebbi
Department of Oncology, School of Medicine Georgetown University Washington District of Columbia USA
6 shared publications - Maryam Marzban
Department of Biostatistics and Epidemiology, Faculty of Health and Nutrition, Bushehr University of Medical Sciences, Bushehr, Iran
6 shared publications - Mohamad Gholizade
The Persian Gulf Tropical Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
6 shared publications - Mohammad Aryaie
Department of Primary Care and Public Health, School of Public Health, Imperial College London, London, UK
6 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Limited evidence is available to acknowledge the association between opium use and liver cancer. In a case–control study, we recruited 117 cases of primary liver cancer (PLC) and 234 age and sex-matched neighborhood controls from 2016 to 2018. We calculated odds ratios (OR) for opium use and 95% confidence intervals (95% CI), using conditional logistic regressions. Compared with non-users the adjusted OR (AOR, 95% CI) for opium use was 6.5 (95% CI, 2.87–13.44). Compared with people who had no history of use, a strong dose–response effect of opium use was observed by amount of use (AOR, 10.70; 95% CI, 3.92–28.70). Cumulative use of opium also indicated that using over 30 gr-year could increase the PLC risk dramatically (AOR, 11.0; 95% CI, 3.83–31.58). Those who used opium for more than 21 years were highly at risk of PLC (AOR, 11.66; 95% CI, 4.43–30.67). The observed associations were significant even among never tobacco smokers (including cigarette and water-pipe smoking).Prevention Relevance:The results of this study indicate that opium use dramatically increased the risk of liver cancer. Because opioids are increasing for medical and non-medical use globally; accordingly, severe health consequences such as liver cancer have to be investigated widely.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Limited evidence is available to acknowledge the association between opium use and liver cancer. In a case–control study, we recruited 117 cases of primary liver cancer (PLC) and 234 age and sex-matched neighborhood controls from 2016 to 2018. We calculated odds ratios (OR) for opium use and 95% confidence intervals (95% CI), using conditional logistic regressions. Compared with non-users the adjusted OR (AOR, 95% CI) for opium use was 6.5 (95% CI, 2.87–13.44). Compared with people who had no history of use, a strong dose–response effect of opium use was observed by amount of use (AOR, 10.70; 95% CI, 3.92–28.70). Cumulative use of opium also indicated that using over 30 gr-year could increase the PLC risk dramatically (AOR, 11.0; 95% CI, 3.83–31.58). Those who used opium for more than 21 years were highly at risk of PLC (AOR, 11.66; 95% CI, 4.43–30.67). The observed associations were significant even among never tobacco smokers (including cigarette and water-pipe smoking).Prevention Relevance:The results of this study indicate that opium use dramatically increased the risk of liver cancer. Because opioids are increasing for medical and non-medical use globally; accordingly, severe health consequences such as liver cancer have to be investigated widely.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Limited evidence is available to acknowledge the association between opium use and liver cancer. In a case–control study, we recruited 117 cases of primary liver cancer (PLC) and 234 age and sex-matched neighborhood controls from 2016 to 2018. We calculated odds ratios (OR) for opium use and 95% confidence intervals (95% CI), using conditional logistic regressions. Compared with non-users the adjusted OR (AOR, 95% CI) for opium use was 6.5 (95% CI, 2.87–13.44). Compared with people who had no history of use, a strong dose–response effect of opium use was observed by amount of use (AOR, 10.70; 95% CI, 3.92–28.70). Cumulative use of opium also indicated that using over 30 gr-year could increase the PLC risk dramatically (AOR, 11.0; 95% CI, 3.83–31.58). Those who used opium for more than 21 years were highly at risk of PLC (AOR, 11.66; 95% CI, 4.43–30.67). The observed associations were significant even among never tobacco smokers (including cigarette and water-pipe smoking).Prevention Relevance:The results of this study indicate that opium use dramatically increased the risk of liver cancer. Because opioids are increasing for medical and non-medical use globally; accordingly, severe health consequences such as liver cancer have to be investigated widely.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Limited evidence is available to acknowledge the association between opium use and liver cancer. In a case–control study, we recruited 117 cases of primary liver cancer (PLC) and 234 age and sex-matched neighborhood controls from 2016 to 2018. We calculated odds ratios (OR) for opium use and 95% confidence intervals (95% CI), using conditional logistic regressions. Compared with non-users the adjusted OR (AOR, 95% CI) for opium use was 6.5 (95% CI, 2.87–13.44). Compared with people who had no history of use, a strong dose–response effect of opium use was observed by amount of use (AOR, 10.70; 95% CI, 3.92–28.70). Cumulative use of opium also indicated that using over 30 gr-year could increase the PLC risk dramatically (AOR, 11.0; 95% CI, 3.83–31.58). Those who used opium for more than 21 years were highly at risk of PLC (AOR, 11.66; 95% CI, 4.43–30.67). The observed associations were significant even among never tobacco smokers (including cigarette and water-pipe smoking).Prevention Relevance:The results of this study indicate that opium use dramatically increased the risk of liver cancer. Because opioids are increasing for medical and non-medical use globally; accordingly, severe health consequences such as liver cancer have to be investigated widely.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
Supplementary Table from Opium Use and the Risk of Liver Cancer: A Case–Control Study
- 23 September 2022
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 16 (1) , 29-35
Opium Use and the Risk of Liver Cancer: A Case–Control Study
Limited evidence is available to acknowledge the association between opium use and liver cancer. In a case–control study, we recruited 117 cases of primary liver cancer (PLC) and 234 age and sex-matched neighborhood controls from 2016 to 2018. We calculated odds ratios (OR) for opium use and 95% confidence intervals (95% CI), using conditional logistic regressions. Compared with non-users the adjusted OR (AOR, 95% CI) for opium use was 6.5 (95% CI, 2.87–13.44). Compared with people who had no history of use, a strong dose–response effect of opium use was observed by amount of use (AOR, 10.70; 95% CI, 3.92–28.70). Cumulative use of opium also indicated that using over 30 gr-year could increase the PLC risk dramatically (AOR, 11.0; 95% CI, 3.83–31.58). Those who used opium for more than 21 years were highly at risk of PLC (AOR, 11.66; 95% CI, 4.43–30.67). The observed associations were significant even among never tobacco smokers (including cigarette and water-pipe smoking). Prevention Relevance: The results of this study indicate that opium use dramatically increased the risk of liver cancer. Because opioids are increasing for medical and non-medical use globally; accordingly, severe health consequences such as liver cancer have to be investigated widely.
- 23 September 2022
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 16 (1) , 29-35
Opium Use and the Risk of Liver Cancer: A Case–Control Study
Limited evidence is available to acknowledge the association between opium use and liver cancer. In a case–control study, we recruited 117 cases of primary liver cancer (PLC) and 234 age and sex-matched neighborhood controls from 2016 to 2018. We calculated odds ratios (OR) for opium use and 95% confidence intervals (95% CI), using conditional logistic regressions. Compared with non-users the adjusted OR (AOR, 95% CI) for opium use was 6.5 (95% CI, 2.87–13.44). Compared with people who had no history of use, a strong dose–response effect of opium use was observed by amount of use (AOR, 10.70; 95% CI, 3.92–28.70). Cumulative use of opium also indicated that using over 30 gr-year could increase the PLC risk dramatically (AOR, 11.0; 95% CI, 3.83–31.58). Those who used opium for more than 21 years were highly at risk of PLC (AOR, 11.66; 95% CI, 4.43–30.67). The observed associations were significant even among never tobacco smokers (including cigarette and water-pipe smoking). Prevention Relevance: The results of this study indicate that opium use dramatically increased the risk of liver cancer. Because opioids are increasing for medical and non-medical use globally; accordingly, severe health consequences such as liver cancer have to be investigated widely.